Cancer Drug Bet Pays Off for Biotech CEO With 3,600% Stock Surge

(Bloomberg) -- When Jan Skvarka joined biotechnology firm Trillium Therapeutics Inc. as chief executive officer, he made a big bet to reshape the company and went all-in on a cancer treatment platf...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.